

The RB and p53 pathways in cancer

Charles J. Sherr^{1,3} and Frank McCormick²

¹Howard Hughes Medical Institute, St. Jude Children's Research Hospital, Memphis, Tennessee 38105

²University of California San Francisco, Cancer Research Institute, San Francisco, California 94115

³Correspondence: sherr@stjude.org

The life history of cancer cells encompasses a series of genetic missteps in which normal cells are progressively transformed into tumor cells that invade surrounding tissues and become malignant. Most prominent among the regulators disrupted in cancer cells are two tumor suppressors, the retinoblastoma protein (RB) and the p53 transcription factor. Here, we discuss interconnecting signaling pathways controlled by RB and p53, attempting to explain their potentially universal involvement in the etiology of cancer. Pinpointing the various ways by which the functions of RB and p53 are subverted in individual tumors should provide a rational basis for developing more refined tumor-specific therapies.

Transformation of cultured primary cells into tumorigenic variants is a multistep process, whereby each genetic change confers a proliferative advantage (Hahn and Weinberg, 2002). The evolution of cancer in living animals is considerably more complex, since specific interactions between tumor cells and host tissues are necessary for tumor angiogenesis, tissue invasion, and metastasis. Yet, despite the existence of many forms of cancer and global changes in gene expression profiles observed in cancer cells versus normal cells, a relatively small number of essential alterations are shared by most, and perhaps all, tumors (Hanahan and Weinberg, 2000). Such mutations can disrupt normal growth control in response to environmental cues, or can dismantle cell cycle checkpoints that otherwise limit cell division or that induce cell suicide in response to DNA damage or oncogene activation. RB and p53 are central to these processes.

Starting and stopping the cell cycle

The proliferation of mammalian cells is normally determined by extracellular signals that engage a program of gene expression and protein regulation required for cell division (Sherr, 1996). During the first gap phase (G1) of the cell division cycle, mitogenic stimulation triggers the activity of key regulatory molecules that initiate DNA synthesis (S phase), after which cells are committed to complete the cycle and divide. In early G1 phase, individual D-type cyclins (D1, D2, and D3), induced in a cell lineage-specific manner, assemble into holoenzyme complexes with one of two catalytic subunits, the cyclin-dependent kinases Cdk4 and Cdk6. These six holoenzymes exhibit similar biochemical functions, and most investigations have focused on the prototypic cyclin D1-Cdk4 complex. Transcription of the *cyclin D1* gene, its synthesis and assembly with Cdk4, and the stability and nuclear retention of the holoenzyme depend strongly on receptor-mediated Ras and phosphatidylinositol 3-kinase (PI3-K) signaling (Marshall, 1999) (Figure 1). Persistent mitogenic stimulation leads to progressive accumulation of cyclin D-dependent kinases within the cell nucleus; here they collaborate with cyclin E-Cdk2 to phosphorylate RB and RB family members p107 and p130, canceling their growth inhibitory functions and facilitating S phase entry.

The activities of cyclin D- and cyclin E-dependent kinases are linked through the agency of the "Cip/Kip" family of Cdk inhibitors, which include p27^{Kip1}, p21^{Cip1}, and p57^{Kip2} (Sherr and Roberts, 1999). Both p27^{Kip1} and p21^{Cip1} are potent inhibitors of cyclin E-

bound Cdk2, but, in living cells, are less effective in blocking the enzymatic activity of cyclin D-bound Cdk4 (Soos et al., 1996; Blain et al., 1997). Instead, the assembly, stability, and nuclear retention of cyclin D1-Cdk4 complexes are facilitated by physical association with Cip/Kip subunits (LaBaer et al., 1997; Cheng et al., 1999; Alt et al., 2002; Muraoka et al., 2002) (Figure 1). These features underscore an important interplay between Cdk4 and Cdk2 during cell cycle entry. In quiescent cells, cyclin D1 levels are low, cyclin D1-Cdk4 complexes do not form, and high levels of p27^{Kip1} suppress cyclin E-Cdk2 activity. Mitogen stimulation induces cyclin D1 and regulates its assembly with Cdk4, thereby sequestering p27^{Kip1} and activating cyclin E-Cdk2 (Figure 2). This pool of p27^{Kip1} remains bound to cyclin D1-Cdk4, whereas the remainder is phosphorylated by cyclin E-Cdk2, triggering its ubiquitination and degradation (Sheaff et al., 1997; Vlach et al., 1997). Both G1 cyclin-dependent kinases can then collaborate in phosphorylating and inactivating RB as cells approach the G1 to S phase transition.

Cell cycle exit following mitogen withdrawal depends upon a reversal of these processes. *Cyclin D1* transcription is cancelled, rapidly leading to destruction of the cyclin D1-Cdk4 holoenzyme. The liberated pool of p27^{Kip1} blocks cyclin E-Cdk2 activity, enabling unphosphorylated p27^{Kip1} to reaccumulate. Inhibition of G1 cyclin-dependent kinases returns RB family proteins to their hypophosphorylated active state, and cells exit the cycle.

The RB-E2F connection

RB, p130, and p107 physically interact with many proteins, but their binding to members of the E2F family of transcription factors appears to be central to their role in governing DNA replication (Dyson, 1998; Nevins, 2001; Trimarchi and Lees, 2002). Complexes between RB family members and various E2Fs actively repress gene expression by recruiting histone deacetylases (HDACs) and other chromatin remodeling factors to E2F-responsive promoters (Harbour and Dean, 2000; Rayman et al., 2002; Ogawa et al., 2002). However, Cdk-mediated phosphorylation of RB family members prevents their association with both HDACs and E2Fs and enables E2F-dependent gene expression (Figure 2). Importantly, E2Fs coordinately regulate genes necessary for DNA replication, including those coding for enzymes required for DNA metabolism and synthesis, as well as cyclins E and A. Hence, the active hypophosphorylated forms of RB family members block entry into S phase by inhibit-




Figure 1. Cyclin D1 activity is regulated by Ras

Ras-dependent signaling through a pathway (gray shading) involving Raf, MEK, and ERK (extracellular signal-regulated kinases) activates transcription factors (e.g., AP1) that upregulate cyclin D1 transcription. Once translated, the assembly of cyclin D1 into active holoenzyme complexes containing Cdk4 and a Cip/Kip protein (p27^{Kip1}) is shown to require signaling through the same Ras pathway (orange shading). Assembly of cyclin D1 with Cdk4, import of stable complexes into the cell nucleus, and their persistence depend upon Cip/Kip proteins. Glycogen synthase kinase-3β (GSK-3β) can phosphorylate cyclin D1 to trigger its nuclear export, ubiquitination, and proteasomal degradation. A distinct Ras-dependent pathway (blue shading) that includes phosphatidylinositol 3-kinase (PI3-K) and the AKT kinase (protein kinase B) negatively regulates GSK-3β to enhance the stability of the cyclin D-dependent kinase.

ing the E2F transcriptional program.

RB itself is nonessential for cell cycle control (Jacks, 1996), and its actual role in governing cell cycle progression in different physiologic settings remains unresolved. For example, recruitment of HDACs to E2F-responsive promoters in normal fibroblasts is largely controlled by p107 and p130 during the cell cycle (Rayman et al., 2002), raising the possibility that RB contributes to gene repression only under certain conditions, such as when cells differentiate or become senescent (Sellers et al., 1998; Lipinski and Jacks, 1999; Thomas et al., 2001). RB preferentially binds to a subset of E2Fs, whereas p107 and p130 associate with others (Dyson, 1998; Nevins, 2001; Trimarchi and Lees, 2002). Apart from E2Fs, RB also interacts with other transcription factors that govern cell differentiation (Dyson, 1998; Sellers et al., 1998; Lipinski and Jacks, 1999; Thomas et al., 2001). Because mutations affecting p107 and p130 occur rarely, if at all, in cancer, such distinctions are key to understanding RB's tumor suppressor function.

The INK4 family


Four INK4 proteins (p16^{INK4a}, p15^{INK4b}, p18^{INK4c}, and p19^{INK4d}) specifically inhibit the activity of cyclin D-dependent kinases to prevent phosphorylation of RB family proteins (Ruas and Peters, 1998; Sherr and Roberts, 1999; Roussel, 1999; Ortega et al., 2002). Disruption of individual *Ink4* genes in the mouse germline and studies with mouse embryo fibroblasts (MEFs) have not revealed profound cell cycle anomalies in *Ink4*-deficient cells. That all four strains of *Ink4* null mice are born at the expected Mendelian ratio and develop normally also implies that no one family member is essential for cell cycle control (Roussel, 1999; Ortega et al., 2002). Yet, mice lacking p16^{INK4a}, in particular, are tumor prone and develop a wide spectrum of

cancers, particularly after exposure to chemical carcinogens or X-rays (Serrano et al., 1996; Krimpenfort et al., 2001; Sharpless et al., 2001). Whereas *Ink4c* and *Ink4d* are broadly expressed during mouse development and in adult tissues, expression of *Ink4a* and *Ink4b* is limited in utero and is sporadic as mice age (Zindy et al., 1997). Therefore, p18^{INK4c} and p19^{INK4d} appear to be primarily dedicated to developmental roles in cell cycle control, whereas p16^{INK4a} and p15^{INK4b} have more restricted functions.

Both p16^{INK4a} and p15^{INK4b} are selectively induced when primary MEFs are explanted into culture (Zindy et al., 1997). A progressive increase in p16^{INK4a} levels as such cells are serially passaged correlates with their diminishing proliferative capacity, arguing for a role for p16^{INK4a} in cellular senescence (Alcorta et al., 1996; Hara et al., 1996; Zindy et al., 1997). Stress stemming from a nonphysiologic cell culture environment generates signals that activate p16^{INK4a} synthesis (Sherr and DePinho, 2000), but its induction can be retarded, or even eliminated, by changing conditions in which primary cells are grown (Ramirez et al., 2001). This argues that p16^{INK4a} plays a specialized role within the *Ink4* family in countering certain signals that abnormally drive cell proliferation, a checkpoint function that is eroded in tumor cells.


The "RB pathway" and cancer

The biochemical activities of the INK4 proteins, cyclin D-dependent kinases, and RB family proteins highlight a pathway controlling G1 phase progression:



There is now compelling evidence that particular components of

Asmita Roy

**Figure 2.** A G1 phase regulatory cascade

Cyclin D1 synthesis (step A) and assembly (step B) in response to mitogenic signals sequesters Cip/Kip proteins (p27^{Kip1} is shown) and relieves cyclin E-Cdk2 from their constraint. Both G1 cyclin-dependent kinases then collaborate to sequentially phosphorylate RB family proteins (only RB is shown) (step C). This frees E2Fs from inhibition and leads to the activation of genes required for S phase entry (step D). Among the known E2F target genes is cyclin E, whose transcriptional upregulation provides positive feedback to drive cells into S phase (step E). One substrate of cyclin E-Cdk2 is p27^{Kip1}, whose phosphorylation triggers its ubiquitination and degradation as cells enter S phase (step F).

this regulatory machinery act as tumor suppressors or protooncogenes, whose mutations occur so frequently as to prompt speculation that disabling "the RB pathway" may be essential for the formation of cancer cells (Sherr, 1996; Sellers and Kaelin, 1997; Nevins, 2001; Hahn and Weinberg, 2002; Ortega et al., 2002). While RB disruption is the *sine qua non* of retinoblastoma, RB loss occurs in many tumor types. Similarly, although mutations inactivating p16^{INK4a} function were first mapped in familial melanoma (Kamb et al., 1994), they have been cataloged in many other cancers (Ruas and Peters, 1998). Mutually exclusive events resulting in RB or p16^{INK4a} inactivation through mutation, deletion, or epigenetic silencing, or in

the overexpression of cyclin D1 or Cdk4, provide genetic evidence for operation of this signaling pathway in tumor surveillance.

Table 1 summarizes approximate frequencies of *INK4a* and *RB* loss of function, and cyclin D1 or Cdk4 overexpression, in different forms of cancer. It is notable that mutations affecting the RB pathway generally occur in a mutually exclusive fashion, so that one "hit" (e.g., *INK4a* mutation) is unaccompanied by others (*RB* mutation or cyclin D-Cdk overexpression). Interestingly, the frequency of particular genetic events varies among tumor types. For example, in lung cancers, RB loss predominates in small cell tumors, whereas p16^{INK4a} loss occurs in the majority of non-small cell carcinomas. In addition, cervical carcinomas and other squamous cell carcinomas frequently express human papillomavirus (HPV) E7 proteins that target RB family members. In cervical carcinomas that do not express HPV E7, RB is inactivated by somatic mutation.

The cause of cyclin D1 overexpression in many tumor types is unknown, although in mantle cell lymphomas, the *cyclin D1* gene is juxtaposed to the immunoglobulin heavy chain promoter enhancer via a t(11:14) translocation. This leads to ectopic expression of cyclin D1 in B lymphocytes, which normally express cyclins D2 and D3 preferentially. In contrast to p16^{INK4a} and RB, which seem to play specific roles in checkpoint control, the selective involvement of particular D-type cyclins in tumorigenesis may also reflect their normal patterns of tissue-specific expression during development. Consistent with observations that D1, and not D2 or D3, is the major D-type cyclin expressed in both retinal and mammary epithelial tissues, mice lacking *cyclin D1* exhibit retinal hypoplasia and defective lobuloalveolar development of breast epithelium during pregnancy (Fantl et al., 1995; Sicinski et al., 1995). Conversely, enforced expression of

Table 1. The RB pathway in human cancer

Cancer type	INK4a loss	Cyclin D1 or Cdk4 overexpression	RB loss
Small cell lung cancer	15%	5% Cyclin D1	80%
Non-small cell lung cancer	58%		20%–30%
Pancreatic cancer	80%		
Breast cancer	30%	>50% Cyclin D1	
Glioblastoma multiforme	60%	40% Cdk4	
T cell ALL	75%		
Mantle cell lymphoma		90% Cyclin D1	

This table summarizes approximate frequencies of *INK4a* loss (by mutation, deletion, or gene silencing), RB mutation or deletion, and cyclin D1 or Cdk4 overexpression in different forms of cancer.

a *cyclin D1* transgene in the breast tissue of mice predisposes to mammary cancer (Wang et al., 1994). Moreover, whereas mice overexpressing *Her2/Neu* or oncogenic *Ras* transgenes targeted to mammary epithelium rapidly develop breast cancer, they fail to do so in a *cyclin D1* null background, indicating that D1 function is essential for tumorigenesis and that other D-type cyclins in breast tissue cannot compensate (Yu et al., 2001). In contrast, mice overexpressing targeted *Wnt* or *Myc* oncogenes develop breast carcinomas in a *cyclin D1* null background, apparently because these oncogenes induce *cyclin D2* (Yu et al., 2001).

The RB pathway is not strictly linear, in the sense that cyclin D1 overexpression not only accelerates the RB-E2F transcriptional program but also leads to p27^{Kip1} sequestration, thereby lowering the Cdk2 threshold (Figure 2). Hence both RB and p27^{Kip1} activity are negatively regulated by cyclin D1. The non-catalytic role of cyclin D1 in sequestering p27^{Kip1} likely plays a role in mammary tumorigenesis. In *Her2/Neu* transgenic mice, mammary carcinoma is accelerated in a p27^{+/−} genetic background but is inhibited in p27^{Kip1} null mice (Muraoka et al., 2002). Thus, lowering the p27^{Kip1} threshold accelerates cancer formation, presumably by relieving inhibition of Cdk2; however, some residual p27^{Kip1} function is essential for tumor development. Notably, cyclin D1-Cdk4 complexes could not stably assemble in cultured mammary epithelial cells from p27^{Kip1} null mice, but could reform when p27^{Kip1} was reintroduced (Muraoka et al., 2002). These findings appear relevant to human breast cancers where cyclin D1 is frequently overexpressed (Bartkova et al., 1994) and where low levels of p27^{Kip1} convey a poor prognosis (Catzavelos et al., 1997; Porter et al., 1997; Cariou et al., 1998).

We still do not understand what particular selective advantage accrues from disruption of the RB pathway. Cells lacking *RB* or *INK4a*, or those overexpressing cyclin D1, do not divide at an accelerated rate. On the other hand, blunted responses to extracellular growth-inhibitory signals may prevent them from terminally differentiating or undergoing senescence. As discussed below, disruption of the RB pathway initiates a compensatory p53-dependent transcriptional program that reinforces cell cycle exit or, more dramatically, triggers apoptosis. In turn, any subsequent failure of p53 function would allow such cells to remain in cycle, abnormally extending cellular lifespan.

Interconnecting RB and p53

Surprisingly, the *INK4a* locus encodes a second gene product, in part from an alternative reading frame that overlaps sequences encoding p16^{INK4a} (Quelle et al., 1995). The alternative reading frame protein (p19^{Arf} in mice and p14^{ARF} in humans) is a potent tumor suppressor that activates p53 (Kamijo et al., 1997). The p53 transcription factor is induced in response to DNA damage, hypoxia, and oncogene activation, and it regulates a program of gene expression that leads either to cell cycle arrest or apoptosis (Levine, 1997; Giaccia and Kastan, 1998). Among the genes induced by p53 are the Cdk inhibitor p21^{Cip1}, many genes encoding proapoptotic proteins, and the p53 negative regulator Mdm2 (Hdm2 in humans) that plays a role in terminating the p53 response. Mdm2 binds directly to p53 to inhibit transcription, and it catalyzes p53 ubiquitination, targeting p53 for degradation (Juven-Gershon and Oren, 1999). In turn, p19^{Arf} binds directly to Mdm2 to antagonize these functions (Sherr, 2001). The *p53* gene is mutated in more than 50% of human cancers, and mutations in other genes that affect p53

function occur in many, if not all, tumors that retain a normal *p53* gene. Among these are mutations affecting *Hdm2*, *ARF*, and a series of transcription factors that control *ARF* and *p53* gene expression. This points to another key signaling circuit in cancer cells:



Both *p53*- and *Arf*-deficient mice spontaneously develop tumors and die of cancers early in life (Jacks, 1996; Kamijo et al., 1999a). Primary MEFs cultured from these animals do not senesce in culture but instead yield immortal cell lines (Harvey and Levine, 1991; Kamijo et al., 1997). In other mouse cell types, both *Arf* loss and silencing of p16^{INK4a} are required for establishment of cell lines, underscoring collaboration between the RB and p53 pathways in this process (Holland et al., 1998; Randle et al., 2001). Human fibroblasts also bypass senescence when both the RB and p53 pathways are disabled, but telomere shortening provides an additional barrier to immortalization that must be overcome through reactivation of telomerase or by telomere stabilization through alternative recombinational mechanisms (Wright and Shay, 2000; Hahn and Weinberg, 2002). These differences between human and mouse cells reflect the presence of longer telomeres on mouse chromosomes and the less active suppression of telomerase activity in mouse versus human somatic cells. Hence, human cells lacking intact RB and p53 checkpoints eventually experience telomere dysfunction, leading to chromosomal end-end joining and fusion-bridge-breakage cycles that trigger the aneuploidy observed in most carcinomas (Hanahan and Weinberg, 2000; Sherr and DePinho, 2000; Wright and Shay, 2000; Hahn and Weinberg, 2002; O'Hagan et al., 2002 [this issue]).

The ability of deregulated E2F to induce *ARF* transcription provides one connection between the RB pathway and p53 (DeGregori et al., 1997; Bates et al., 1998) and may help to explain why most tumors have defects in the p53 pathway. Overexpression of E2F in established cell lines lacking *ARF* or *p53* can enforce S phase entry even in the absence of mitogenic stimulation (Johnson et al., 1993; Qin et al., 1994; Shan and Lee, 1994), but nonimmortal human diploid fibroblasts instead undergo an *ARF*-dependent p53 response leading to G1 phase arrest and, later, to apoptosis (Lomazzi et al., 2002). Enforced overexpression of p19^{Arf} in primary MEFs induces cell cycle arrest (Quelle et al., 1995), whereas induction of *Arf* by ectopically expressed E2F1 or by certain oncoproteins, such as Myc or adenovirus E1A (see below), is accompanied by apoptosis (De Stanchina et al., 1998; Zindy et al., 1998). *Arf* deficiency partially protects cells from apoptosis induced by these proteins. However, in mouse tumor models lacking functional RB or overexpressing E2F, *Arf* loss does not invariably diminish apoptosis or accelerate tumorigenesis (Russell et al., 2002; Tolbert et al., 2002; Tsai et al., 2002), indicating that E2F can activate p53 through *Arf*-independent pathways. By interfering with Mdm2, p19^{Arf} enhances p53 stability and blocks cell proliferation, but further posttranslational modifications of p53 are likely to be required for induction of the apoptotic program (Kamijo et al., 1999b; Khan et al., 2000; Lin et al., 2001; Rogoff et al., 2002). Understanding *Arf* dependency in some circumstances and not others requires further investigation.

Further complexity stems from the fact that Rb-E2F acts both upstream and downstream of the p19^{Arf}-p53 axis. MEFs lacking all three Rb family proteins do not senesce in culture

Asmita Roy




Figure 3. Cell autonomous tumor surveillance and therapeutic options

Mitogenic signaling activates E2Fs and Myc to advance cells into S phase. Stress signals that activate the *Ink4a-Arf* locus inhibit the activity of cyclin D-dependent kinases ($p16^{Ink4a}$) and induce p53 through either Arf-dependent or -independent pathways, reprogramming cells to undergo growth arrest or apoptosis. Ras can also induce Mdm2 expression through a p53-independent pathway, further restraining the p53 response in Arf null cells. Protooncogenes are shown in green and tumor suppressors in red. Sites for therapeutic intervention are indicated in blue.

and are resistant to $p19^{Arf}$ -induced cell cycle arrest (Dannenberg et al., 2000; Sage et al., 2000). One possible interpretation is that the antiproliferative activity of $p19^{Arf}$ might strongly depend upon the ability of the p53-inducible Cdk inhibitor, $p21^{Cip1}$, to inhibit phosphorylation of Rb family members. However, cells lacking $Cip1$ are not immortal and undergo efficient $p19^{Arf}$ -induced arrest (Pantoja and Serrano, 1999; Modestou et al. 2001). A mutant form of E2F (E2F-DB) that binds to DNA but neither interacts with Rb nor transactivates E2F target genes can displace Rb-E2F complexes from promoters. When this mutant was overexpressed in primary MEFs, disruption of Rb-E2F-mediated repression increased the expression of E2F target genes, including *Arf* (Rowland et al., 2002). Despite the activation of a persistent $p19^{Arf}$ -mediated p53 response, cells expressing E2F-DB were immortal and resistant to ectopic overexpression of either $p19^{Arf}$ or p53. Therefore, Rb (family)-E2F-mediated repression is required for cell cycle exit in response to $p19^{Arf}$ -p53 activation. Defining the relevant E2F target genes remains an open question, although genes encoding functions necessary for S phase entry are reasonable candidates.

Arf is induced by abnormal mitogenic signals stemming from activated or overexpressed oncoproteins such as Myc, adenovirus E1A, mutated Ras, v-Abl, and β -catenin (Sherr, 2001). Activation of the Arf-Mdm2-p53 pathway reroutes cells that have sustained oncogenic damage to alternative p53-dependent fates—growth arrest or apoptosis (Figure 3). Disruption of this pathway eliminates this form of tumor surveil-

lance and enables oncogenes to drive uncontrolled cell proliferation. By inducing *Arf* and *Ink4a* in primary rodent fibroblasts, oncogenic Ras expression leads to growth arrest and premature senescence (Serrano et al., 1997; Ferbeyre et al., 2002). However, Ras transforms established rodent cell lines lacking *Arf* or *p53* into tumor cells.

An independent Ras-activated pathway induces Mdm2 in *Arf* null cells, which further dampens the p53 response and makes such cells resistant to chemotherapeutic agents that depend on p53 function to induce apoptosis (Ries et al., 2000). Akt-mediated phosphorylation of Mdm2 enhances its nuclear translocation and collaborates in destabilizing the p53 protein (Mayo and Donner, 2001).

Overexpression of Myc in primary MEFs triggers apoptosis and strongly selects for the appearance of surviving cells that have lost either Arf or p53 function (Zindy et al., 1998). Mice bearing a *Myc* transgene under the control of a B cell-specific immunoglobulin promoter enhancer ($E\mu$ -Myc) develop Burkitt-type lymphomas with an average latency of six months (Adams et al., 1985). In early stages of disease, increased S phase entry by B cells in lymph nodes is counterbalanced by apoptosis (Eischen et al., 1999; Schmitt et al., 1999). $E\mu$ -Myc overexpression gradually selects for cells that lose Arf or p53 function, so that the majority of lymphomas that arise bear such mutations (Eischen et al., 1999). Crossing $E\mu$ -Myc transgenic mice onto an *Arf*^{-/-} genetic background accelerates the formation of tumors, most of which lose the wild-type *Arf* allele. The effects of $E\mu$ -Myc in *Arf* null mice are particularly dramatic, with all ani-

mals dying of aggressive lympholeukemias by only six weeks of age.

Although *Arf* disruption accelerates E μ -*Myc*-induced lymphomagenesis by blunting apoptosis, p16^{Ink4a} loss does not; strikingly, however, *Ink4a* mutations render mice resistant to potentially curative chemotherapy (Schmitt et al., 2002). When lymphomas arising in E μ -*Myc* transgenic mice were transplanted into cohorts of naive recipients, tumors lacking *Ink4a-Arf* responded poorly to cyclophosphamide, whereas those lacking *Arf* alone could be cured. In this setting, p16^{Ink4a} and p53 collaborate to enable execution of a drug-induced senescence program. This establishes different roles for *Arf* and *Ink4a* during tumor development and indicates that p16^{Ink4a} loss can interrupt a genetic program that facilitates drug-induced cytostasis. Loss of p53 portends a poorer prognosis, since p53 is required for both apoptosis and cytostasis (Schmitt et al., 2002).

Susceptibility to familial melanoma was mapped to the *INK4a-ARF* locus, and the critical mutations in some kindreds affect p16^{INK4a} but not p14^{ARF} function (Kamb et al., 1994). However, mice lacking *Ink4a-Arf* rarely develop melanoma unless crossed with animals that express a *Ras* transgene in appropriate target cells (Chin et al., 1997; Bardeesy et al., 2001). When animals containing a mutant *Ink4a* allele were crossed with mice lacking the entire *Ink4a-Arf* locus, heterozygotes spontaneously developed melanomas, and dimethylbenzanthrene treatment resulted in a higher frequency of aggressive tumors (Krimpenfort et al., 2001). Thus, a subtle constellation of genetic events involving p16^{Ink4a} inactivation and *Arf* haploinsufficiency programs a different outcome than complete loss of *Ink4a-Arf*, which predisposes to other tumor types (Serrano et al., 1996).

Although an abnormal threshold of mitogenic signals has the potential to activate both *Ink4a* and *Arf*, neither gene is broadly expressed at significant levels during fetal development (Zindy et al., 1997). *Bmi-1*, a transcriptional repressor, actively shuts off both genes, allowing rapid cell divisions to take place in utero without activation of the RB and p53 checkpoints. *Bmi-1* disruption leads to developmental anomalies in multiple organ systems that are reversed on an *Ink4a-Arf* null background (Jacobs et al., 1999a). As might be expected, then, overexpression of *Bmi-1* accelerates E μ -*Myc*-induced lymphomagenesis by dampening p19^{Arf} and p16^{Ink4a} expression (Jacobs et al., 1999b). Similarly, overexpression of other *ARF* repressors, such as *Twist* and *TBX2*, occurs in several forms of human cancer that retain wild-type p53 (Maestro et al., 1999; Jacobs et al., 2000). Thus, tumors with normal *ARF*, *Hdm2*, and p53 genes can still exhibit defective p53 function.

Opportunities for targeted therapy

Defects in apoptosis and cell cycle checkpoint control not only affect tumor development, but also contribute to multidrug resistance (Johnstone et al., 2002; Schmitt et al., 2002). How then can we exploit known genetic defects in the RB and p53 pathways to rationally design effective anticancer treatment?

Therapies based on the RB pathway

Disruption of cyclin D-Cdk complexes should prevent tumor progression in cases where specific D-type cyclins are overexpressed, or where "upstream" oncproteins rely upon particular D-type cyclins for their effects. Although most cell types synthesize more than one D-type cyclin and produce both Cdk4 and Cdk6, the selective expression of cyclin D1 and Cdk4 in breast epithelium (Fantl et al., 1995; Sicinski et al., 1995) and the strict

dependency on cyclin D1 for development of certain breast tumors (Yu et al., 2001) argues for a role of cyclin D1 antagonists in the treatment this disease. Since it remains unclear whether the catalytic (Cdk activation) or stoichiometric (p27^{Kip1} sequestration) functions of cyclin D1 are required for breast tumorigenesis, inhibitors that block cyclin D1 synthesis or assembly with Cdk4 would be ideal, since they would interfere with both processes. However, preventing the assembly of cyclins with Cdks using small molecules presents a formidable challenge, because of the extensive interfaces that underlie their molecular interactions (Pavletich, 1999). Another approach may be to interfere with Ras-dependent kinase signaling cascades required for cyclin D1-Cdk4 assembly. The Raf and PI3K signaling cascades that govern cyclin D1 synthesis, stability, and Cdk assembly (Figures 1 and 3) are central to Ras-dependent antiapoptotic functions and are themselves targets of oncogenic activation in many tumor types. Hence, pharmacological development of selective inhibitors of these pathways has long been underway, and many are already in clinical trials for cancer treatment (Herrera and Sebolt-Leopold, 2002). Cdk inhibitors (Gray et al., 1988; Hoessel et al., 1999; Fry et al., 2001; Soni et al., 2001; Nahta et al., 2002) might also prove useful in treating tumors that overexpress cyclin D1-Cdk4 or that have lost *INK4a* function (Figure 3). However, because certain Cdks play non-cell-cycle roles in processes such as transcription and neural development, modulation of Cdk function, if not highly specific, could well have unanticipated side effects in nonproliferating cells (Sausville, 2002). Some recently developed compounds exhibit more selectivity for Cdk4 and Cdk6 (Toogood, 2001), but target validation *in vivo* remains a problem.

The adenovirus E1A protein binds to RB family proteins to release E2Fs and promote S phase entry. Apart from activating many E2F-responsive cellular genes, including *E2F1* itself, E2Fs regulate the *E2* region of the adenoviral genome—indeed, this is how E2F activity was first recognized. Moreover, the *E1* region of the adenovirus genome encodes a protein (E1orf6/7) that binds directly to E2Fs, displacing RB and selectively directing E2F to both the viral *E2* promoter and to the cellular *E2F1* promoter. An adenovirus expressing a mutant form of E1A that cannot bind RB should replicate selectively and kill cells lacking functional RB (Fueyo et al., 2000). A variant in which both the viral *E1* and mutant *E1A* genes are placed under the control of the human *E2F1* promoter selectively kills tumor cells with deregulated E2F, whereas normal cells halt viral replication in an RB-dependent manner (Johnson et al., 2002). Such viruses are effective and relatively safe systemic antitumor agents in xenograft models. Using additional variants with increased potential for lysing cycling cells should provide even further specificity and efficacy against tumor cells (Doronin et al., 2000).

Increased E2F activity in tumor cells upregulates a number of enzymes that are already targets for therapy. Indeed, classical anticancer agents such as methotrexate and 5-fluorouracil act on E2F-regulated gene products (dihydrofolate reductase and thymidylate synthase, respectively). These agents are often effective, but patients become refractory, frequently through mutations in the target genes. A complementary approach might take advantage of synthetic lethality, in which disruption of one of two genes that affect a vital function is compatible with life, whereas loss of both causes cell death. For example, cells that lack RB and manifest defects in E2F regulation are much more sensitive than normal cells to cyclin A-Cdk2 inhibitors